CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05708950
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:04.330939+00:00
Published At: 2023-07-13T00:00:00+00:00
Record Updated At: 2023-07-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Solid Tumor", "Melanoma", "Carcinoma", "Sarcoma", "Lung Cancer", "Prostate Cancer", "Breast Cancer", "Colo-rectal Cancer", "Uterine Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Thyroid Cancer", "Ovarian Cancer", "Kidney Cancer", "Head and Neck Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-07-13"
protocolSection.identificationModule.nctId: "NCT05708950"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.